Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.

Javed SR. et al, (2024), Br j cancer

An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma.

Baxter MA. et al, (2024), Esmo open, 9

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).

Spiliopoulou P. et al, (2024), J exp clin cancer res, 43

New role of fat-free mass in cancer risk linked with genetic predisposition.

Harris BHL. et al, (2024), Sci rep, 14

CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.

Javed SR. et al, (2024), Br j cancer, 130, 467 - 475

Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.

Henriksen PA. et al, (2023), Circulation, 148, 1680 - 1690

Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases.

Pagnamenta AT. et al, (2023), Genome med, 15

Predicting 10-year breast cancer mortality risk in the general female population in England: a model development and validation study.

Clift AK. et al, (2023), Lancet digit health, 5, e571 - e581

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

Coombes RC. et al, (2023), Nat commun, 14

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.

Macaulay VM. et al, (2023), Br j cancer

Early phase antitumour clinical trials and palliative medicine.

Virani F. et al, (2023), Bmj support palliat care

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.

Charles Coombes R. et al, (2023), Nat commun, 14

Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.

Carroll TM. et al, (2023), Cancer cell, 41, 1222 - 1241.e7

Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study.

Clift AK. et al, (2023), Bmj, 381

Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?

Lord SR. and Harris AL., (2023), Br j cancer, 128, 958 - 966

Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2023)

Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2023)

Supplementary Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2023)

Supplementary Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2023)

Supplementary Figure from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2023)

Load More

Include forthcoming?